Exelixis is transforming the challenges of drug development into opportunities to create innovative therapies with significant clinical and commercial potential.

Corporate Profile

Exelixis, Inc. was founded and incorporated in 1994, and we are currently based in South San Francisco, California. Exelixis, from the Greek word for “evolution,” is a biopharmaceutical company committed to the discovery, development and commercialization of new medicines to improve care and outcomes for people with cancer.

Over the past fifteen years, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. The history of our lead compounds, cabozantinib and cobimetinib, tells the story of our evolution as a company. Each of these compounds was discovered in our own laboratories and advanced by us into clinical development.<More >>

EXEL (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$26.94
Change (%) Stock is Up 0.03 (0.11%)
Volume1,671,821
Data as of 08/16/17 12:52 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
08/16/17Exelixis Submits U.S. Supplemental New Drug Application for CABOMETYX® (cabozantinib) for the Treatment of Previously Untreated Advanced Kidney CancerPrinter Friendly Version
08/02/17Exelixis Announces Second Quarter 2017 Financial Results and Provides Corporate UpdatePrinter Friendly Version
08/01/17Exelixis-Discovered Compounds to Be Featured in 10 Presentations at ESMO 2017 CongressPrinter Friendly Version
07/20/17Exelixis Announces Settlement of Dispute with Genentech Regarding Companies’ Collaboration Agreement for CobimetinibPrinter Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Featured Report
Download Documentation2016 Annual Report (pdf)
Download Documentation2015 Annual Report (pdf)

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.